Novartis’ Sandoz to appeal US district court ruling on biosimilar Erelzi
The United States District Court of New Jersey gave ruling against Sandoz over the validity of the two patents that describe and claim Enbrel and the methods for
Superluminal Medicines secured $120m in a Series A funding round to advance the development of its assets into clinical trials.
The company has announced positive OS results from the phase III randomised, double-blinded and multi-centre trial of Tagrisso in previously-untreated patients with locally-advanced or metastatic non-small cell lung
Vesselon will use Imagent to create novel therapeutic complexes in four classes of cancer drugs: cytokines, oncolytic viruses, monoclonal antibodies, and nucleic acid constructs. Vesselon incorporates Imagent into
Results from the trial showed a statistically-significant and clinically-meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) with Lynparza vs. enzalutamide or abiraterone in men with